The stock slipped 2.97 per cent to settle at Rs 2,336.20 on BSE. During the day, it lost 4.51 per cent to Rs 2,299.
At NSE, shares of the company dipped 2.91 per cent to end at Rs 2,339.
Also Read
In four trading sessions, the company's shares have fallen by nearly 4 per cent.
Meanwhile, BSE earlier in the day sought clarification from the company on reports that Dr Reddy's shares fell on the buzz of issues raised in EIR for Duvvada plant.
It later clarified that, "the company has already intimated the stock exchanges on November 21, 2017 regarding the updated status of USFDA audit of our formulations manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh and has no further update."
Further, the movement in price of company's scrip is completely market driven and hence the company has no comments to offer on share price movement, the filing added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)